A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients

J Clin Psychopharmacol. 1991 Dec;11(6):344-50.

Abstract

We studied the efficacy of propranolol (Inderal) compared to alprazolam (Xanax) in 29 patients with a diagnosis of agoraphobia with panic disorder or panic disorder with or without limited phobic avoidance in a 6-week double-blind controlled experiment. Alprazolam is effective in those syndromes, whereas to date only negative or ambiguous results had been reported for propranolol. Fourteen patients received a mean daily dose of 5.0 +/- 2.3 mg of alprazolam and 15 patients received 182.0 +/- 60.5 mg mean daily dose of propranolol. We found both drugs to be effective to suppress panic attacks and reduce avoidance behavior. The only significant between-drug difference was a more rapid onset of alprazolam's panicolytic effect. Propranolol merits further study. We suggest patients worthy of a clinical trial.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Agoraphobia / drug therapy*
  • Agoraphobia / psychology
  • Alprazolam / adverse effects
  • Alprazolam / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Panic / drug effects
  • Panic Disorder / drug therapy*
  • Panic Disorder / psychology
  • Personality Assessment / statistics & numerical data
  • Propranolol / adverse effects
  • Propranolol / therapeutic use*
  • Psychometrics

Substances

  • Propranolol
  • Alprazolam